Experimental CAR T-Cell therapy targets two proteins to fight tough lymphoma
NCT ID NCT06295549
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This early-phase trial tested a new cell therapy called LUCAR-G39P in 11 patients with relapsed or refractory B-cell non-Hodgkin lymphoma. The therapy uses a patient's own immune cells, modified to attack two targets (CD19 and CD20) on cancer cells. The main goals were to check safety, side effects, and find the right dose. The study was terminated early, so results are limited.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- LUCAR-G39P cells (a type of CAR T-cell therapy that targets two proteins, CD19 and CD20, on cancer cells)
- What this could lead to
- If this therapy works, it could offer a new treatment option for patients with hard-to-treat B-cell lymphoma that has come back after other treatments.
- What could go wrong
- This is a very early phase 1 trial with only 11 patients, and it was terminated early. The therapy may cause serious side effects, and it is unknown if it will be effective or safe for broader use.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for RELAPSED AND REFRACTORY B-CELL NON-HODGKIN LYMPHOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Affiliated Hospital of Nantong University
Nantong, Jiangsu, 226001, China
-
Beijing Gobroad Hosptial
Beijing, 102206, China
-
Department of Haematology, the First Affiliated Hospital of Nanjing Medical University, Jiangsu Province Hospital
Nanjin, Jiangsu, 210029, China
More trials for these conditions
Other studies related to the condition(s) this trial covers.